{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018210","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.357711+00:00","generated_at":"2026-06-23T12:38:44.762051+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LENSAR applies for CE Mark certification of ALLY System in European Union","bullets":["Application for CE Mark certification of the ALLY Adaptive Cataract Treatment System submitted.","CE Mark would allow commercialization of ALLY in the European Union following successful certification.","Application follows U.S. FDA clearance of ALLY in June 2022 and the U.S. commercial launch.","Company plans to use distributor network for EU commercialization, similar to first-generation system."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018210","json":"https://secwatch.observer/filing/0000950170-22-018210.json","markdown":"https://secwatch.observer/filing/0000950170-22-018210.md","text":"https://secwatch.observer/filing/0000950170-22-018210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000095017022018210/0000950170-22-018210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000095017022018210/lnsr-20220908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T12:38:44.762051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}